Geetha P. Bansal, PhD
Clinical Associate Professor
Department of Tropical Medicine
Director, Interdisciplinary Innovative Programs Hub
Tulane University School of Public Health and Tropical Medicine
1440 Canal Street, Suite 2301, Room 2311 #8317
New Orleans, LA 70112
Please visit the I2PH page for additional information.
Dr. Bansal has gathered vast experience in immunology, vaccine development and infectious disease research over the last twenty five years. Her specific interest is in B cell responses, developing hybridomas for monoclonal antibody production and antibody based vaccine and prevention approaches, understanding mechanisms of immunological responses to infection and elicitation of protective vaccine induced responses. Her more general interest and experience is in infectious diseases and prevention science, and bridging basic, biomedical and social, behavioral sciences research. She currently teaches graduate level immunology course and mentors graduate students in laboratory based research, provides training and assistance to junior and senior faculty with grant writing and in formulating scientific and administrative requirements for an effective application. Harnessing her previous experience as a scientific review officer and program officer at the NIH, she has developed and teaches a graduate level course "Essentials in Research Readiness Skills" which incorporates elements of Responsible Conduct of Research, Ethics and Grant Writing and Management.As Director, Interdisciplinary Innovative Programs Hub (I2PH) she also works on projects focused on Research Enhancement and Development for Faculty, Fellows and Students, and facilitates interdisciplinary training for research and training by holding a variety of cross-cutting activities that promote networking among disciplines, collaborative research and practice and learning through discussion forums. As a member of the Vector Borne Infections Diseases Research (VBIDRC). She collaborates with researchers from School of Medicine and School of Science and Engineering.
Vaccine immunology, vaccine design, infectious disease research (including HIV and malaria), antibody based prevention and treatment research, adjuvants, innate immunity and antigen presentation, improving DNA vaccines, malaria transmission blocking strategies, monoclonal antibody development
- B.Sc., Physics, Delhi University, New Delhi, India, 1972
- M.Sc., Biophysics, All India Inst. Med. Sciences, New Delhi, India, 1975
- Ph.D., Biochemistry/Immunology, University of Maryland, College Park, MD, 1985
- Post-Doctoral Fellow, Immunology, NIH, Bethesda, MD, 1985-88
- 1988 - 1995 Director, Department of Antibody and Vaccine Discovery, MedImmune Inc., Gaithersburg, MD
- 1996 - 2002 Primary Patent Examiner, U.S. Patent and Trademark Office, Dept. Commerce, US Govt.
- 2002 - 2005 Scientific Review Administrator, DEA, NIAID, NIH, Bethesda, MD
- 2005 - 2010 Program Officer, Division of AIDS, NIAID, NIH, Bethesda, MD
- 2007- 2010 Project Officer, Los Alamos HIV/SIV Sequence and Immunology database
- 2011 - 2014 Associate Dean for Research, Tulane University School of Public Health and Tropical Medicine
- 2011 - 2014 Deputy Director, Center for Infectious Diseases, Tulane University
- 2011 - present Associate Professor, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine
- 2012 - present Director, Interdisciplinary Innovative Programs Hub (I2PH), School of Public Health and Tropical Medicine
- 2002 Granted a current license by the USPTO to serve as a Patent Agent
- AI-08-007 - Highly Innovative Tactics to Interrupt Transmission of HIV (HIT-IT) (R01) (July 17, 2008)
- AI-08-053 – Basic HIV Vaccine Discovery Research (R01) (August 27, 2008)
- AI-09-037 - Highly Innovative Tactics to Interrupt Transmission of HIV (HIT-IT) (R01) (July 1, 2009)
- AI-07-031 - U.S.-India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-morbidities (R21) (October 18, 2007)
- AI-09-022 - B Cell Immunology Partnership Program For HIV-1 Vaccine Discovery (U19) (June 16, 2009)
- AI-10-001 - Mechanisms and Prevention of Sexual Transmission of HIV/SIV (R01) (February 25, 2010)
- AI-10-022 - U.S.-India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co-morbidities (R21) (May 18, 2010)
- Examined and issued over 200 patents in vaccines, Monoclonal based Immunotherapeutics for infectious disease and cancer
- NIH - Small Business Innovation Research Grant Phase 1- (Sept. 1990 - March 1991). Surrogate assay for B 19 Parvovirus Serum Neutralization (Principal Investigator)
- NIH - Small Business Innovation Research Grant Phase I - (May 1 - Oct. 31, 1994). Human Monoclonal Antibodies for Respiratory Syncytial Virus (Principal Investigator)
- NIH - Small Business Innovation Research Grant Phase I - (Funded to begin 1st quarter 1995). Lyme Disease Vaccine Using Gonococcal Blebs (co-investigator)
- NIH - Small Business Innovation Research Grant Phase I - Immunogenicity of an in vivo expressed protein of Borrelia burgdorferi (co-investigator)
- Examined and issued over 200 patents in vaccines, Monoclonal based Immunotherapeutics and vaccines for infectious disease and cancer 1996-2002)
- NIH – Training Grant: Fogarty Global Health Fellows Coordinating Center – Co-Director (2012 – 2017)
- NIH – Training Grant: Interamerican Transdisciplinary Training for Innovations in Emerging Infectious Diseases (2012-2017)
- NIH - Identification of transmission blocking epitopes on P. vivax 48/45 protein (Dec. 2014-Nov. 2016) Principal Investigator
- 2011-present: Academic Editor for PLoS One
- 1996 - present: Reviewer, National Science Books and Film Association, American Association for the Advancement of Science, Washington D.C. Manuscript reviewer: J. Immunology, Clinical and Diagnostic Laboratory Immunology, Clinical and Vaccine Immunology, PLOS One, Malaria Journal, Abstracts Reviewer for International AIDS Society Conferences.
Other Experiences and Professional Memberships
- 1999: NIH, NIAID Special Emphasis Panel to review contract proposals on Integrated Preclinical/Clinical AIDS Vaccine Development.
- 1999: NIH, NIAID Special Emphasis Panel to review contract proposals on HIV Vaccine Design and Development Teams.
- 1994: NIH, NIAID study section to review grants on Immune Responses to Lyme Disease.
- 1993-1996: NIH, standing study section member, the AIDS Research Review Committee, NIH Advisory Committee.
- 1993: Reviewer, National Research Council Board on Science and Technology for International Development.
- NIH/NIAID Merit awards in 2008 for contributions to the US-India Bilateral collaborative Research Program and for the DAIDS-DAIT B-cell Immunology Program
- Recognized by NIAID/Division of AIDS exemplary for performance and special acts every year from 2005 – 2010
- NIH/NIAID Merit award in 2005 for conducting the peer review of grant applications submitted to the highly complex VATID Biodefense Program
- Recognized by NIAID/Scientific Review Program for exemplary performance and special acts every year from 2002 - 2004.
- Granted a license by the USPTO to serve as Patent Agent in 2002.
- Member, American Association for the Advancement of Science.
- Secretary, Sigma-Xi, Scientific Research Society - Washington D.C. Chapter.
Selected Publications and Presentations:
For a complete list of publications, please click on the following link:
Merino KM, Bansal GP, Kumar N. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulfide bonds- evaluating effect of GILT. Immunology. 2016 May 14. doi: 10.1111/imm.12621.
Bansal GP, Weinstein CS, Kumar N. Insight into phagocytosis of mature sexual (gametocyte) stages of Plasmodium falciparum using a human monocyte cell line. Acta Trop. 2016 May;157:96-101. doi: 10.1016/j.actatropica.2016.01.033. Epub 2016 Feb 3. PubMed PMID: 26851166; PubMed Central PMCID: PMC4779693.
Kumar R, Ledet G, Graves R, Datta D, Robinson S, Bansal GP, Mandal T, Kumar N. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res. 2015 Dec;32(12):3827-36. doi: 10.1007/s11095-015-1743-x. Epub 2015 Jun 26. PubMed PMID: 26113235; PubMed Central PMCID: PMC4628851.
Kumar R, Ray PC, Datta D, Bansal GP, Angov E, Kumar N. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine. 2015 Sep 22;33(39):5064-71. doi: 10.1016/j.vaccine.2015.08.025. Epub 2015 Aug 20. PubMed PMID: 26299750; PubMed Central PMCID: PMC4577455.
Datta D, Bansal GP, Kumar R, Ellefsen B, Hannaman D, Kumar N. Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice. Clin Vaccine Immunol. 2015 Sep;22(9):1013-9. doi: 10.1128/CVI.00185-15. Epub 2015 Jul 1. PubMed PMID: 26135972; PubMed Central PMCID: PMC4550670.
Bansal GP, Leitner WW. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010. Vaccine. 2010 Dec 6;28(52):8229-35. doi: 10.1016/j.vaccine.2010.10.073. Epub 2010 Nov 10. PubMed PMID: 21073990.
Bansal GP, Malaspina A, Flores J. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther. 2010 Feb;12(1):39-46. Review. PubMed PMID: 20140815.
Girard MP, Bansal GP, Pedroza-Martins L, Dodet B, Mehra V, Schito M, Mathieson B, Delfraissy JF, Bradac J. Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October 2007. Vaccine. 2008 Jul 29;26(32):3969-77. doi: 10.1016/j.vaccine.2008.04.051. Epub 2008 May 8. PubMed PMID: 18513838.
Girard MP, Bansal GP. HIV/AIDS vaccines: a need for new concepts? Int Rev Immunol. 2008;27(6):447-71. doi: 10.1080/08830180802432160. Review. PubMed PMID: 19065351.
Level of Instruction:
[View all Tropical Medicine faculty]